Author

Art J. Kudla

Observed names: A J Kudla, A Kudla, A. Kudla, A.J. Kudla, Art Kudla

Institution: Pfizer (United States)

Observed institutions: Roswell Park Comprehensive Cancer Center, Pfizer (United States), Purdue University West Lafayette, Merrimack Pharmaceuticals (United States)

OpenAlex ID: A5113850128

Differentially expressed fibroblast growth factors regulate skeletal muscle development through autocrine and paracrine mechanisms.

1996 · K Hannon, A J Kudla, et al. · The Journal of Cell Biology · 127

DNA damage response and tumorigenesis in Mcm2-deficient mice

2010 · D Kunnev, M E Rusiniak, et al. · Oncogene · 96

Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)

2017 · Birgit Schoeberl, Art Kudla, et al. · npj Systems Biology and Applications · 73

Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).

2016 · Crystal Shereen Denlinger, Maria Alsina Maqueda, et al. · Journal of Clinical Oncology · 23

A Data-Driven Computational Model of the ErbB Receptor Signaling Network

2006 · Birgit Schoeberl, Emily Pace, et al. · 12

Health-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) receiving glasdegib + azacitidine (AZA).

2020 · Eunice S. Wang, Timothy Bell, et al. · Journal of Clinical Oncology · 8

Hydra reaggregation: a rapid assay to predict teratogenic hazards induced by environmental toxicity

1984 · Art Kudla · Biodiversity Heritage Library (Smithsonian Institution) · 4

Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence.

2020 · Amer Methqal Zeidan, Michael Schuster, et al. · Journal of Clinical Oncology · 3

A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)

2016 · L.V. Sequist, I. Anderson, et al. · Annals of Oncology · 3

A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).

2016 · Lecia V. Sequist, Ian Churchill Anderson, et al. · Journal of Clinical Oncology · 3

Abstract A14: A randomized trial of exemestane +/- seribantumab (MM-121) in postmenopausal women with locally advanced or metastatic ER/PR+ HER2- breast cancer: Final analysis and extended subgroup analysis

2017 · Greg Finn, Hong Zhang, et al. · Clinical Cancer Research · 2

Biomarker Analysis of a Phase 1 Study of Mm-111, a Bispecific Her2/Her3 Antibody Fusion Protein, in Combination with Multiple Treatment Regimens in Patients with Advanced Her2 Positive Solid Tumors

2014 · A. Kudla, B. Adiwijaya, et al. · Annals of Oncology · 2

Abstract P1-07-03: Quantification of HER2 expression at the single cell level and HER2 intratumoral heterogeneity of breast cancer tissue samples using automated image analysis

2012 · E Geretti, V Paragas, et al. · Cancer Research · 2

Abstract A205: Development and application of a platform for analysis of protein biomarkers in clinical biopsies of limited quantity.

2013 · Jinyan Du, Johanna Lahdenranta, et al. · Molecular Cancer Therapeutics

MM-121: a human monoclonal antibody ErbB3 antagonist

2008 · Birgit Schoeberl, Kip A. West, et al. · Cancer Research

Works count: 16

Citation count: 358

H-index: 6

I10-index: 5